[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583513":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":31,"studyPopulation":19,"armGroups":32,"interventions":39,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":78,"collaborators":19,"id":81,"slug":19,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":19,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":19,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":64,"whyStopped":19,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Sichuan University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":19},[9],{"measure":10,"description":11,"timeFrame":12},"pCR rate","pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin stained slides of the resected lung specimen and lymph nodes following completion of neoadjuvant therapy","From date of enrollment until one month after resection",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"MPR rate","mPR is defined as ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes.",{"measure":18,"description":19,"timeFrame":12},"R0-resection rate",null,{"measure":21,"description":22,"timeFrame":23},"Event-free survival (EFS)","EFS is defined as the time from enrollment to radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause.","up to 2 years",{"allocation":25,"interventionModel":26,"interventionModelDescription":27,"primaryPurpose":28,"observationalModel":19,"timePerspective":19,"maskingInfo":29},"NA","SINGLE_GROUP","Single Group Assignment","TREATMENT",{"masking":30,"maskingDescription":19,"whoMasked":19},"NONE","All eligible patients will receive LDRT combined with partial SBRT, followed by PD-1 inhibitors plus platinum-based chemotherapy, initiated within 7 days after completing radiation. PD-1 inhibitors and chemotherapy will be administered at the recommended doses according to the instruction manual every 3 weeks, with 3 cycles planned as neoadjuvant therapy. Surgery will be performed within 4 to 6 weeks (+7 days) after completing the final cycle of immunochemotherapy.\n\nMain objective and endpoint: the rate of pathological complete response (pCR) in the resected primary tumor and lymph nodes.",[33],{"label":34,"type":35,"description":36,"interventionNames":37},"Radiation therapy combined with PD-1 inhibitor and chemotherapy group","EXPERIMENTAL","Low-Dose Radiation(2Gy\\*2-3d) +Stereotactic body radiation therapy (10Gy\\*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 3 cycles before surgical resection.",[38],"Drug: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",[40],{"type":41,"name":42,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",[34],[45,46],"Drug: Tislelizumab","Drug: Chemotherapy",[48],{"name":49,"affiliation":50,"role":51},"You Lu, MD. PhD","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":19,"email":57},"Jianxin Xue, MD. Phd","CONTACT","18982251798","killercell@163.com",{"name":49,"role":55,"phone":59,"phoneExt":19,"email":60},"+86 189 8060 1763","radyoulu@hotmail.com",[62],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":66,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"West China Hospital of Sichuan University","RECRUITING","Chengdu","China","610041","CN",{"type":70,"coordinates":71},"Point",[72,73],104.06667,30.66667,{"lat":73,"lon":72},[76],{"name":77,"role":55,"phone":56,"phoneExt":19,"email":57},"Jianxin Xue, MD. PhD",{"type":51,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"You Lu","Chair of Division of Thoracic Tumor Multimodality Treatment","100583513",false,"NCT06877299","Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","Low-Dose Radiation + Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients With Resectable StageⅡA-ⅢB Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years;\n2. Patients with untreated stage IIA-IIIB non-small cell lung cancer, diagnosed cytologically or histologically (according to the AJCC 9th edition of thoracic tumor staging);\n3. Pulmonary lesions will be assessed as resectable or potentially resectable by a multidisciplinary team, including a thoracic surgeon;\n4. At least one imaging-measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1);\n5. Ability to provide tumor tissue or cell wax blocks that meet quality control standards for PD-L1 expression testing.\n\nExclusion Criteria:\n\n1. The pathology is small cell lung cancer (SCLC), including lung cancer mixed with SCLC and non-small cell lung cancer (NSCLC)；\n2. Patients with known EGFR-sensitive mutations or ALK fusion.\n3. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T cell receptors;\n4. Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;\n5. Active infection requiring systemic treatment.","ALL","18 Years","75 Years",{"count":91,"type":92},30,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.",[98,99],"Lung Cancer","Non-small Cell Lung Cancer",[101,102,103,104,105],"Neoadjuvant","Low Dose Radiotherapy","Stereotactic Body Radiotherapy","Immunotherapy","NSCLC","2025-12-29",{"date":108,"type":109},"2026-01-02","ACTUAL",{"date":111,"type":109},"2025-07-04",{"date":113,"type":92},"2028-01-01",{"name":5,"class":6},1]